Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total International Bond Index Fund ETF vs Revvity Inc — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $48.04, while Revvity Inc trades at $111.15 (market cap $12.41B). The key difference: Revvity Inc pays a 0.25% dividend while Vanguard Total International Bond Index Fund ETF pays none, and Revvity Inc is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BNDX | RVTY | |
|---|---|---|
52-Week High | $49.91 | $117.75 |
52-Week Low | $47.57 | $82.26 |
Market Cap | — | $12.41B |
Sector | — | Technology |
Enterprise Value | — | $14.90B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNDX trades at $47.89, down 0.4% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators but faces pressure from rising bond yields and Fed uncertainty. Recent news highlights strong bond ETF inflows as investors seek yield amid market volatility, though inflation concerns persist.
Outlook remains cautious due to potential Fed rate hikes and macroeconomic headwinds. The fund offers steady income through dividends but faces valuation pressure from rising rates. Key risks include interest rate sensitivity and global economic shifts impacting international bond performance.
RVTY trades at $111.11, down 1.05% today, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.06 exceeding expectations. Recent developments include AI integration with Anthropic's Claude and FDA clearance for a testosterone assay, signaling innovation in diagnostics and life sciences.
The outlook remains positive with strong analyst support (51.72% buy ratings) and a consensus price target of $111.43. Key risks include margin pressure from China divestment plans and weak academic demand. Revenue stability around $2.9B supports valuation, though high P/E of 53.47 requires sustained growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
